Hoji Alimi

Mr. Alimi has over 20 years of experience in the healthcare industry and has raised more than $170 million in capital throughout his career for different ventures. In 1999, he founded Micromed Laboratories Inc. to assist drug and device companies to navigate FDA and European Conformity (“CE”) mark approval processes. In 2002, Mr. Alimi founded Oculus Innovative Sciences, Inc., a company focused on topical anti- infective drugs as well as device-related applications. As CEO and Chairman, he led the company to successfully complete a randomized, double-blind, controlled phase II trial for improvement or cure of infection in diabetic ulcers. Under his tenure, the company became publicly traded on Nasdaq and achieved dozens of regulatory approvals, including CE marks and 510(K) FDA clearances. In 2012, he founded Ruthigen, Inc. to focus on the development of a drug compound for the reduction of hospital acquired infections during invasive abdominal procedures. As CEO, Chairman and CSO, Ruthigen, Inc. completed an initial public offering and traded on NASDAQ, and later merged with Pulmatrix, a pulmonary-focused pharmaceutical company. Hoji Alimi holds more than 30 patents in areas of anti-infective, surgical, wound care and manufacturing of specific drugs and devices. He received his B.A. in Biology - Sonoma State University 1995.